Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFIRM: BG00012 in Relapsing-Remitting Multiple Sclerosis
NCT00451451Phase 3Completed
- Sponsor
- Biogen
- Start
- Jun 2007
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by Biogen. Primary endpoint: Annualized Relapse Rate at 2 years. Started Jun 2007; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00451451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451451.